

**EXECUTIVE SUMMARY
OF THE
OPTN/UNOS BOARD OF DIRECTORS MEETING
June 5-6, 2017
Richmond, VA**

Stuart Sweet, MD, OPTN/UNOS President, called the meeting to order at 10:05 a.m. on June 6, 2017. A quorum was present, and 38 of the Board members were in attendance in person or by electronic means of communications.

During the first day of the meeting, the Board approved several resolutions contained in the Consent Agenda in a single vote. The subject of the individual resolutions approved in the Consent Agenda follows here:

1. The Board accepted the 2016 OPTN audit report for the period ended September 30, 2016.
2. The Board approved the minutes of the December 5-6, 2016 meeting of the Board of Directors held in St. Louis, MO; and the April 27, 2017 Board of Directors meeting by conference call.
3. The Board approved the appointment of OPTN/UNOS Committee Chairs as follows:

Elisa Gordon, PhD, MPH	Ethics
Nicole Turgeon, M.D., FACS	Kidney
Julie Heimbach, M.D.	Liver and Intestinal Organs
Jon Odorico, M.D.	Pancreas
Jennifer Milton, BSN, CCTC, MBA	Policy Oversight
Sylvia Rosas, M.D., MSCE	Minority Affairs
Sarah Nicholas, BSN, RN, CCTC	Transplant Coordinators
4. The Board approved the guidance document entitled *Guidance on Explaining Risk Related to Use of U.S. PHS Increased Risk Donor Organs When Considering Organ Offers*.
5. The Board approved the guidance document entitled *Guidance Document for OPTN/UNOS Histocompatibility Laboratory Bylaws and Policies*.
6. The Board approved changes to. *Bylaws Article II: Board of Directors, Article III: Nominating Committee, Article IV: Executive Committee, Article VI: Officers, and Article IX: Regions* that address vacancies on the Board and Executive Committee.

Following passage of the consent agenda, the Board approved clarifications to the following equivalency tables in Policy 4: Table 4-2 (HLA A Matching Antigen Equivalences), Table 4-3 (HLA B 2 Matching Antigen Equivalences), Table 4-4 (HLA DR Matching Antigen Equivalences), Table 4-6 3 (HLA B Unacceptable Antigen Equivalences), and Table 4-12 (HLA DQB1 Unacceptable Antigen 4 Equivalences).

Dr. Sweet gave a report of the Executive Committee, followed by UNOS CEO Brian Shepard who provided a report on operations.

The Board approved the OPTN 2017-2018 operating budget and related OPTN patient registration fee, which will remain at \$834.

After extensive discussion, the Board *declined* to approve changes to Policies 2.11.A (Required Information for Deceased Kidney Donors) and 8.6 (Double Kidney Allocation) that would have modified the allocation of en bloc kidneys.

The Board approved changes to Policies 9.3 (Score and Status Exceptions), Bylaws 9.3 (Regional Review Boards), and Bylaws Appendix M (Definitions) that establish a national liver review board, as well as the related guidance documents entitled *Guidance to Liver Transplant Programs and the National Liver Review Board for Adult MELD Exception Review*, *Guidance to Liver Transplant Programs and the National Liver Review Board for Pediatric MELD/PELD Exception Review*, and *Guidance to Liver Transplant Programs and the National Liver Review Board for Adult MELD Exceptions for Hepatocellular Carcinoma (HCC)*.

Dr. Sweet gave his Presidential Address.

The Board received presentations regarding an update on the Systems Optimization project, and on the efforts of the Liver and Intestinal Organ Transplantation Committee on the liver redistribution project.

The meeting adjourned at 1:50 p.m. on June 6, 2017.

Secretary's Note: Prior to the open session of the meeting, the Board met in closed session to consider member actions recommended by the Membership and Professional Standards Committee. The Board placed a transplant hospital on Probation, and released a histocompatibility laboratory member from Probation and restored it to full membership.